Knight Therapeutics (GUD) News Today C$6.01 +0.04 (+0.67%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Knight Therapeutics Inc. (TSE:GUD) Insider Sells C$15,750,000.00 in StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 2,500,000 shares of the firm's stock in a transaction on Friday, March 21st. The stock was sold at an average price of C$6.30, for a total value of C$15,750,000.00.March 25 at 3:59 PM | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 2,500,000 SharesMarch 25 at 4:04 AM | insidertrades.comResearch Analysts Issue Forecasts for TSE:GUD Q4 EarningsKnight Therapeutics Inc. (TSE:GUD - Free Report) - Research analysts at Raymond James issued their Q4 2025 EPS estimates for Knight Therapeutics in a note issued to investors on Thursday, March 20th. Raymond James analyst M. Freeman forecasts that the company will post earnings of $0.01 per shareMarch 24 at 2:20 AM | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 550,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 550,000 shares of Knight Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of C$6.20, for a total transaction of C$3,410,000.00.March 21, 2025 | marketbeat.comCollective, Knight at 52-Week Highs on NewsMarch 21, 2025 | baystreet.caSime Armoyan selling more Knight Therapeutics (GUD)March 20, 2025 | theglobeandmail.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 92,200 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 92,200 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of C$6.15, for a total transaction of C$567,030.00.March 19, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 12-Month High - Here's WhyKnight Therapeutics (TSE:GUD) Hits New 12-Month High - Still a Buy?March 19, 2025 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 92,200 Shares of StockMarch 19, 2025 | insidertrades.comKnight Therapeutics (TSE:GUD) Raised to Strong-Buy at Research CapitlResearch Capitl raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday.March 15, 2025 | marketbeat.comKnight Therapeutics price target raised to C$8 from C$7.50 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comKnight Therapeutics (TSE:GUD) Stock Price Up 9.2% - Still a Buy?Knight Therapeutics (TSE:GUD) Trading 9.2% Higher - Here's WhyMarch 12, 2025 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Purchases 17,600 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 17,600 shares of Knight Therapeutics stock in a transaction dated Tuesday, March 4th. The shares were bought at an average price of C$5.48 per share, for a total transaction of C$96,488.48.March 6, 2025 | marketbeat.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Buys 17,600 Shares of StockMarch 6, 2025 | insidertrades.comKnight Therapeutics (TSE:GUD) Trading Up 1.4% - Here's WhyKnight Therapeutics (TSE:GUD) Trading Up 1.4% - Should You Buy?February 18, 2025 | marketbeat.comKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for OnicitJanuary 31, 2025 | finanznachrichten.deKnight Therapeutics (TSE:GUD) Shares Down 0.2% - What's Next?Knight Therapeutics (TSE:GUD) Shares Down 0.2% - Should You Sell?January 28, 2025 | marketbeat.comGot $4,000? 4 Healthcare Stocks to Buy and Hold ForeverJanuary 27, 2025 | fool.caKnight Therapeutics (TSE:GUD) Trading Up 0.6% - Time to Buy?Knight Therapeutics (TSE:GUD) Trading Up 0.6% - Here's WhyJanuary 4, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 2.5% - Here's What HappenedKnight Therapeutics (TSE:GUD) Trading Down 2.5% - What's Next?December 13, 2024 | marketbeat.comSime Armoyan Purchases 90,300 Shares of Knight Therapeutics Inc. (TSE:GUD) StockNovember 16, 2024 | insidertrades.comKnight Therapeutics (TSE:GUD) Upgraded at Raymond JamesRaymond James raised shares of Knight Therapeutics to a "moderate buy" rating in a research report on Friday.November 16, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 90,300 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan acquired 90,300 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.44.November 15, 2024 | marketbeat.comQ4 Earnings Estimate for TSE:GUD Issued By Raymond JamesKnight Therapeutics Inc. (TSE:GUD - Free Report) - Research analysts at Raymond James issued their Q4 2024 EPS estimates for shares of Knight Therapeutics in a research report issued on Wednesday, November 13th. Raymond James analyst R. Sarugaser expects that the company will post earnings per shNovember 15, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Buys 20,000 SharesNovember 12, 2024 | insidertrades.comStifel Canada Issues Negative Outlook for TSE:GUD EarningsKnight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Stifel Canada reduced their Q4 2024 EPS estimates for Knight Therapeutics in a research report issued on Thursday, November 7th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of $0.06 perNovember 11, 2024 | marketbeat.comKnight Therapeutics (GUD) Set to Announce Earnings on ThursdayKnight Therapeutics (TSE:GUD) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 0.3% - Time to Sell?Knight Therapeutics (TSE:GUD) Stock Price Down 0.3% - Here's WhyOctober 15, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 300,000 SharesSeptember 22, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sells C$1,839,000.00 in StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 300,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.September 21, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Sets New 52-Week High at $6.23Knight Therapeutics (TSE:GUD) Hits New 1-Year High at $6.23September 17, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Stock Price Up 7.3%Knight Therapeutics (TSE:GUD) Stock Price Up 7.3%September 11, 2024 | marketbeat.comAmal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockAugust 21, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 5,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 5,000 shares of the company's stock in a transaction on Monday, August 19th. The stock was sold at an average price of C$5.78, for a total value of C$28,919.00.August 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Knight Therapeutics Inc.'s FY2024 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Stifel Canada cut their FY2024 EPS estimates for shares of Knight Therapeutics in a report released on Monday, August 12th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of $0.06 for the year, downAugust 15, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Upgraded at Stifel CanadaStifel Canada raised shares of Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday.August 14, 2024 | marketbeat.comStifel Canada Weighs in on Knight Therapeutics Inc.'s Q3 2024 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Analysts at Stifel Canada decreased their Q3 2024 earnings per share (EPS) estimates for shares of Knight Therapeutics in a research report issued on Monday, August 12th. Stifel Canada analyst J. Keywood now forecasts that the company will earn $August 14, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Rating Increased to Buy at Stifel NicolausStifel Nicolaus upgraded Knight Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from C$5.75 to C$6.75 in a research note on Tuesday.August 13, 2024 | marketbeat.comKnight Therapeutics Inc. (GUD.TO)August 12, 2024 | ca.finance.yahoo.comFY2025 EPS Estimates for Knight Therapeutics Inc. Lifted by Raymond James (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Investment analysts at Raymond James raised their FY2025 earnings per share estimates for Knight Therapeutics in a report released on Thursday, August 8th. Raymond James analyst R. Sarugaser now expects that the company will post earnings of $0.0August 12, 2024 | marketbeat.comKnight Therapeutics earnings: here's what to expectAugust 8, 2024 | markets.businessinsider.comKnight Therapeutics Inc. (KHTRF)July 24, 2024 | finance.yahoo.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 10,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of C$5.70, for a total value of C$57,000.00.July 11, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 SharesJuly 4, 2024 | insidertrades.comAmal Khouri Sells 20,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockJune 15, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 20,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00.June 13, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Director Buys C$29,000.00 in StockJune 6, 2024 | insidertrades.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Director Buys 5,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Director Jonathan Ross Goodman bought 5,000 shares of the stock in a transaction dated Wednesday, June 5th. The stock was bought at an average cost of C$5.80 per share, for a total transaction of C$29,000.00.June 5, 2024 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Director Sells 15,000 Shares of StockMay 30, 2024 | insidertrades.comGUD:CA Knight Therapeutics Inc.May 15, 2024 | seekingalpha.com Remove Ads Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address GUD Media Mentions By Week GUD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GUD News Sentiment▼0.420.68▲Average Medical News Sentiment GUD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GUD Articles This Week▼141▲GUD Articles Average Week Remove Ads Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRON News TLRY News ACB News WEED News CPH News OGI News CRDL News RX News HLS News SUGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:GUD) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
